CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $0, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.89BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%Beta
-0.1970xvs all stocks
52-Week Change
114.87%vs all stocks
Market Capitalization
1.89BUSDvs all stocks (USD)
Enterprise Value
1.62BUSDvs all stocks (USD)
Forward P/E
-13.44xPrice to Book (MRQ)
6.92xEnterprise to EBITDA
-10.19xProfit Margin
0.00%Operating Margin
0.00%Return on Assets (TTM)
-38.79%Return on Equity (TTM)
-63.26%Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 17, 2026Gross Profit (TTM)
-95.89MUSDvs all stocks (USD)
EBITDA (TTM)
-158.80MUSDvs all stocks (USD)
Net Income (TTM)
-150.11MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-120.40MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-71.52MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
0.00USDFY2025 · Dec 31, 2025Cost of Goods Sold
0.00USDFY2025 · Dec 31, 2025Gross Profit
0.00USDFY2025 · Dec 31, 2025Operating Income
-153.29MUSDvs all stocks (USD)
Pre-tax Income
-144.69MUSDFY2025 · Dec 31, 2025Income Tax Expense
46.00KUSDFY2025 · Dec 31, 2025Net Income
-144.74MUSDFY2025 · Dec 31, 2025EBIT
-153.29MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-152.77MUSDFY2025 · Dec 31, 2025Research & Development
90.40MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
62.89MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
9.30MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-144.74MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-115.20MUSDFY2025 · Dec 31, 2025Free Cash Flow
-115.34MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
227.64MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-144.74MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
525.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
27.64MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-169.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
383.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
580.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
568.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-138.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-231.82MUSDFY2025 · Dec 31, 2025Sale of Investments
246.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
14.04MUSDFY2025 · Dec 31, 2025Other Financing Charges
252.95MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
252.95MUSDFY2025 · Dec 31, 2025Shares Outstanding
111.03MSharesUpdated Jul 17, 2026Float Shares
83.55MSharesUpdated Jul 17, 2026Shares Short
14.39MSharesUpdated Jul 17, 2026Short Ratio
7.80daysvs all stocks
Short % of Shares Outstanding
16.74%vs all stocks
% Held by Insiders
7.89%vs all stocks
% Held by Institutions
105.37%vs all stocks
Total Cash (MRQ)
279.77MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.52USDUpdated Jul 17, 2026Total Debt (MRQ)
5.63MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0206xCurrent Ratio (MRQ)
17.85xBook Value per Share (MRQ)
2.46USDUpdated Jul 17, 2026Total Assets
332.64MUSDvs all stocks (USD)
Total Current Assets
323.67MUSDFY2025 · Dec 31, 2025Total Liabilities
27.39MUSDFY2025 · Dec 31, 2025Total Non-current Assets
8.97MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
4.70MUSDFY2025 · Dec 31, 2025Total Current Liabilities
22.69MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
226.65MUSDFY2025 · Dec 31, 2025Other Short-term Investments
90.33MUSDFY2025 · Dec 31, 2025Accounts Receivable
88.00KUSDFY2025 · Dec 31, 2025Accounts Payable
3.52MUSDFY2025 · Dec 31, 2025Short-term Debt
1.26MUSDFY2025 · Dec 31, 2025Long-term Debt
4.70MUSDFY2025 · Dec 31, 2025Common Stock (Book)
11.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-751.43MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
305.26MUSDvs all stocks (USD)
52-Week Low
7.48USDUpdated Jul 17, 202652-Week High
19.15USDUpdated Jul 17, 202652-Week Change
114.87%vs all stocks
Beta
-0.1970xvs all stocks
50-Day MA
15.45USDUpdated Jul 17, 2026200-Day MA
14.56USDUpdated Jul 17, 2026Avg 10-Day Volume
1.27MSharesUpdated Jul 17, 2026Avg 30-Day Volume
1.70MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
-1.42USDUpdated Jul 17, 2026Other Income / Expense
-700.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $1.89B, above the global median of $1.15BNotable
Market cap (USD): 1,892,391,115Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Hugel Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
AbCellera Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Nanjing Vazyme Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tyra Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
UFP Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fagron NV
Tier 1ProductionApproval-Gated PipelineFlowRule
Galapagos NV
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zenas BioPharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jafron Biomedical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule